Viatris Inc. (NASDAQ: VTRS, "Viatris" or the "Company") announced today that it and its subsidiaries, Mylan Inc. ("Mylan") and Utah Acquisition Sub Inc. ("Utah Acquisition" and, together with...

Late-Breaking oral presentation shows that cenerimod for the treatment of moderate to severe systemic lupus erythematosus (SLE) in Japanese patients can be considered safe and well-tolerated Data...

Strong Results Demonstrate Power of Company's Diversification, Execution and Growing Base Business Total Revenues of $3.8 Billion and Operational Revenue Growth of ~2% on a Divestiture-Adjusted...

Viatris Inc. (NASDAQ: VTRS) today announced that on August 5, 2024, its Board of Directors declared a quarterly dividend of $0.12 per share for each issued and outstanding share of the Company's...

Achievement of This Major Milestone Further Simplifies and Strengthens the Company and Positions Viatris to Achieve its Key Priorities and Accelerate Future Growth PITTSBURGH, July 3, 2024 /PRNewswire

Viatris Inc. (NASDAQ: VTRS) today announced that the Antitrust Division of the U.S. Department of Justice ("DOJ") has advised that it no longer considers Mylan, and its former President, Rajiv...

Viatris Inc. (NASDAQ: VTRS), a global healthcare company, today announced that the European Commission (EC) has approved the planned divestiture of substantially all of Viatris’ Over-the-Counter (OTC) business to Cooper Consumer Health (CCH).

Viatris Inc. (NASDAQ: VTRS), a global healthcare company, today announced that it has been named to the inaugural edition of TIME's World's Most Sustainable Companies 2024. This recognition is...